Clinical Trials

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06732401 2026-03-18

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Phase 3 Suspended

630 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07195695 2026-03-18

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3 Recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05198830 2026-03-17

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

42 enrolled

Adenocarcinoma of Lung, Lung Neoplasms

NCT07221253 2026-03-17

AB02

Phase 3 Recruiting

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06667908 2026-03-16

CONVERGE

130 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06780137 2026-03-16

MK-6070-002

Phase 1/2 Recruiting

262 enrolled

Small Cell Lung Carcinoma

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Phase 2 Completed

5 enrolled 13 charts

Cholangiocarcinoma

NCT05687266 2026-03-13

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06083454 2026-03-13

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

1 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07332351 2026-03-13

TRIFECTA

33 enrolled

Urinary Bladder Neoplasms

NCT06287775 2026-03-12

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase 1/2 Recruiting

45 enrolled

Phase 1 Not yet recruiting

Lung Neoplasms

NCT07391670 2026-03-12

IMFINZI-subQ

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT05061550 2026-03-11

NeoCOAST-2

630 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05632809 2026-03-11

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

39 enrolled

Lung Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Phase 1 Recruiting

20 enrolled

Phase 2 Not yet recruiting

Gastroesophageal Adenocarcinoma

NCT07459634 2026-03-10

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

50 enrolled

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT05514132 2026-03-09

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

14 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT06728410 2026-03-09

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

38 enrolled

Cholangiocarcinoma

NCT06859684 2026-03-09

HAIC-quad

25 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06963346 2026-03-09

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Phase 1 Suspended

12 enrolled

Urinary Bladder Neoplasms

NCT03847428 2026-03-06

EMERALD-2

908 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04705818 2026-03-06

CAIRE

Phase 2 Completed

164 enrolled

GastrointestinalSarcoma

Tertiary Lymphoid Structures, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT05170204 2026-03-06

HORIZON 1

71 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05696782 2026-03-06

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

28 enrolled

Phase EARLY_PHASE1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

54 enrolled

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT05941897 2026-03-05

LOTOS

Phase 2 Active not recruiting

39 enrolled